A comparative study of bivalirudin plus clopidogrel versus bivalirudin plus prasugrel in primary angioplasty using propensity score matching

Journal of Interventional Cardiology

Volumn 26, Issue 5, 2013, Pages 463-469

  Díaz De La Llera, Luis S ^a   Cubero Gómez, José M ^a   Rangel, Diego ^a   Parejo, Juan ^a   Acosta, Juan ^a   Fernández Cisnal, Agustín ^a   Zafra, Francisco ^a   Benezet, Javier ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; HIRULOG; PRASUGREL;

ACUTE HEART INFARCTION; ADULT; ARTICLE; BLEEDING; CARDIOVASCULAR EFFECT; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; COMPARATIVE STUDY; FEMALE; HEART DEATH; HEART INFARCTION; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROPENSITY SCORE; RETROSPECTIVE STUDY; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS; THROMBOCYTE AGGREGATION INHIBITION; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANGIOPLASTY; ANTITHROMBINS; COHORT STUDIES; DRUG COMBINATIONS; FEMALE; HIRUDINS; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PEPTIDE FRAGMENTS; PIPERAZINES; POSTOPERATIVE COMPLICATIONS; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; THIOPHENES; THROMBOSIS; TICLOPIDINE;

EID: 84885391950     PISSN: 08964327     EISSN: 15408183     Source Type: Journal    
DOI: 10.1111/joic.12058     Document Type: Article

References (17)

1. Wijns W, Kolh P, Danchin N, et al. Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC). The European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2010; 31: 2501-2555.
2. Stone GW, Witzenbichler B, Guagliumi G, et al. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 2008; 358: 2218-2230.
3. Wallentin L, Varenhorst C, James S, et al. Prasugrel achieves greater, faster P2Y12 receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Eur Heart J 2008; 29: 21-30.
4. Wiviott SD, Trenk D, Frelinger AL, et al. Prasugrel compared with high loading-, maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: The Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation, Aggregation-Thrombolysis In Myocardial Infarction 44 trial. Circulation 2007; 116: 2923-2932.
5. Montalescot G, Wiviott SD, Braunwald E, et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet 2009; 373: 723-731.
6. Angiolillo DJ, Badimon JJ, Saucedo JF, et al. A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus, coronary artery disease: Results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 trial. Eur Heart J 2011; 32: 838-846.
7. Díaz de la Llera LS, Fournier Andray JA, Gõmez Moreno S, et al. Transradial approach in the percutaneous treatment of acute myocardial infarction with coronary stents. Rev Esp Cardiol 2004; 57: 732-736.
8. Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: A case for standardized definitions. Circulation 2007; 115: 2344-2351.
9. Rao AK, Pratt C, Berke A, et al. Thrombolysis In Myocardial Infarction (TIMI) Trial-Phase I: Haemorrhagic manifestations, changes in plasma fibrinogen, the fibrinolytic system in patients treated with recombinant tissue plasminogen activator, streptokinase. J Am Coll Cardiol 1988; 11: 1-11.
10. D'Agostino RB Jr., Propensity scores in cardiovascular research. Circulation 2007; 115: 2344-2351.
11. Jolly SS, Yusuf S, Cairns J, et al. Radial versus femoral access for coronary angiography, intervention in patients with acute coronary syndromes (RIVAL): A randomised, parallel group, multicentre trial. Lancet 2011; 377: 1409-1420.
12. Sibbing D, Busch G, Braun S, et al. Impact of bivalirudin or unfractionated heparin on platelet aggregation in patients pre-treated with 600 mg clopidogrel undergoing elective percutaneous coronary intervention. Eur Heart J 2008; 29: 1504-1509.
13. Dangas G, Mehran R, Guagliumi G, et al. Role of clopidogrel loading dose in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty: Results from the HORIZONS-AMI (harmonizing outcomes with revascularization, stents in acute myocardial infarction) trial. J Am Coll Cardiol 2009; 54: 1438-1446.
14. Holmes DR, Kereiakes DJ, Garg S, et al. Stent thrombosis. J Am Coll Cardiol 2010; 56: 1357-1365.
15. Moser LR, Nemerovski CW, Good KL., Use of prolonged bivalirudin infusions following percutaneous coronary intervention. Cardiovasc Drugs Ther 2011; 25: 267-276.
16. Maree AO, Fitzgerald DJ., Variable platelet response to aspirin clopidogrel in atherothrombotic disease. Circulation 2007; 115: 2196-2207.
17. von Beckerath N, Taubert D, Pogatsa-Murray G, et al. Absorption, metabolization, antiplatelet effects of 300-, 600-, 900-mg loading doses of clopidogrel: Results of the ISAR-CHOICE (Intracoronary Stenting, Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) trial. Circulation 2005; 112: 2946-2950.